The impact of amaranth oil supplementation on the expression of early markers of atherosclerosis in overweight and obese patients - randomized nutritional study

The impact of amaranth oil supplementation on the expression of early markers of atherosclerosis in overweight and obese patients - randomized nutritional study - Amaranth oil and atherosclerosis

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

DRKS

Registry ID

DRKS00014046

Enrollment

Registered

2018-03-05

Start date

2015-02-24

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

I70 E66

Interventions

Group 1: Amaranth oil extracted from Amaranthus cruentus and applied per os in doses by 20 ml per day for 3 weeks respectively: in second nutrition intervention in group I and in first nutritional int

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: BMI greater than or equal to 25

Exclusion criteria

Exclusion criteria: history of chronic systemic disease, celiac disease, liver disease, exocrine pancreatic insufficiency, current or recent (within preceding month) treatment with conjugated linoleic acid current treatment with agents interfering with fat digestion/absorption (chitosan, orlistat, green tea).

Design outcomes

Primary

Measure	Time frame
High-sensitivity C-reactive protein (hsCRP) (ELISA method- ELISA Kit Oxis, International Inc., Foster City, USA). Blood samples collected on the baseline visit, first control visit (after 3 weeks of intervention) and after 3 weeks of second nutritional intervention	—

Secondary

Measure	Time frame
The following parameters: - Adhesion molecules: sP-selectin, sVCAM-1 (ELISA method: Human sVCAM-1 Quantikine ELISA Kit; R&D Systems, Minneapolis, USA; Human P-selectin/CD62P ELISA Kit, R&D Systems, Minneapolis, USA), - Asymmetric dimethylarginine (ADMA) (ELISA method: quantitive ELISA test – BioVendor, R&D Systems, Minneapolis, USA), - Apolipoproteins: A-1, B, E (nephelometric method BN2, Siemens, Germany) - Adiponectin (ELISA method - Acrp30 Quantikine ELISA Kit; R&D Systems, Minneapolis, USA) - Lipid profile (total cholesterol, TG, HDL, LDL – enzymaric-colorimetric method - Biomerieux Poland, Warsaw, Poland; ox LDL - ELISA method- oxLDL-bet2GPI-ELISA Kit, Cayman Chemical, Michigan, USA). Blood samples collected on the baseline visit, first control visit (after 3 weeks of first nutritional intervention) and after 3 weeks of second nutritional intervention.	—

Measure

Time frame

The following parameters: - Adhesion molecules: sP-selectin, sVCAM-1 (ELISA method: Human sVCAM-1 Quantikine ELISA Kit; R&D Systems, Minneapolis, USA; Human P-selectin/CD62P ELISA Kit, R&D Systems, Minneapolis, USA), - Asymmetric dimethylarginine (ADMA) (ELISA method: quantitive ELISA test – BioVendor, R&D Systems, Minneapolis, USA), - Apolipoproteins: A-1, B, E (nephelometric method BN2, Siemens, Germany) - Adiponectin (ELISA method - Acrp30 Quantikine ELISA Kit; R&D Systems, Minneapolis, USA) - Lipid profile (total cholesterol, TG, HDL, LDL – enzymaric-colorimetric method - Biomerieux Poland, Warsaw, Poland; ox LDL - ELISA method- oxLDL-bet2GPI-ELISA Kit, Cayman Chemical, Michigan, USA). Blood samples collected on the baseline visit, first control visit (after 3 weeks of first nutritional intervention) and after 3 weeks of second nutritional intervention.

—

Countries

Poland

Contacts

Public ContactJaroslaw Walkowiak

Department of Pediatric Gastroenterology and Metabolic DiseasesPoznan University of Medical Sciences

jarwalk@ump.edu.pl+48 618491432

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 14, 2026